/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2019
CRA Reports Highest Q1 Revenue in Its History;
Broad-based Contributions Across Service Portfolio Drive Revenue
Growth of 6.4% Year-over-Year
BOSTON–(BUSINESS WIRE)–Charles
River Associates (NASDAQ: CRAI), a worldwide leader in providing economic,
financial and management consulting services, today announced
financial results for the fiscal first quarter ended March 30, 2019.
Key First-Quarter Fiscal 2019 Highlights
-
Revenue grew 6.4% year over year to $105.8 million. On a constant
currency basis relative to the first quarter of fiscal 2018 (“constant
currency basis”), revenue would have been higher by $1.5 million,
resulting in year-over-year revenue growth of 7.9%. -
Utilization was 75%, as quarter-end headcount increased by 40, or
6.2%, year over year. -
Net income was $4.7 million, or 4.4% of revenue, compared with $4.9
million, or 4.9% of revenue, in the first quarter of fiscal 2018;
non-GAAP net income was $4.5 million, or 4.3% of revenue, compared
with $5.3 million, or 5.3% of revenue, in the first quarter of fiscal
2018. On a constant currency basis, GAAP and non-GAAP net income would
have been lower by $0.1 million. -
Earnings per diluted share were $0.56, compared with $0.57 in the
first quarter of fiscal 2018; non-GAAP earnings per diluted share were
$0.54, compared with $0.61 in the first quarter of fiscal 2018. On a
constant currency basis, GAAP and non-GAAP earnings per diluted share
would have been lower by $0.01 per diluted share. -
Non-GAAP EBITDA was $8.5 million, or 8.0% of revenue, compared with
$8.6 million, or 8.7% of revenue, in the first quarter of fiscal 2018.
On a constant currency basis, non-GAAP EBITDA would have been lower by
$0.1 million. -
Net income, earnings per diluted share, and non-GAAP EBITDA for the
current period reflect a foreign currency loss of approximately
$750,000 related to the revaluation and realized gains and losses on
working capital balances. -
CRA returned $6.0 million of capital to its shareholders, consisting
of $1.7 million of dividend payments and $4.3 million for share
repurchases of approximately 87,000 shares.
Management Commentary
“I am pleased to report the highest first quarter revenue in CRA’s
history,” said Paul
Maleh, CRA’s President and Chief Executive Officer. “We completed
the quarter with strong performances across our portfolio of practices,
once again demonstrating the continued dedication and hard work of our
entire team. We delivered 75% company-wide utilization while headcount
increased by 6.2%, translating into 7.9% year-over-year revenue growth
on a constant currency basis. On the bottom line, we delivered non-GAAP
net income of $4.5 million, or $0.54 per diluted share. These results
were affected by a foreign currency loss, which reduced our non-GAAP net
income and earnings per diluted share by approximately $0.6 million and
$0.07, respectively.
“Looking more closely at the first quarter, we exhibited strength across
our geographic footprint,” Maleh said. “Our North American operations
grew 6.0%, and our European operations, led by the Antitrust &
Competition Economics practice, grew 7.9% year over year. We also
continued to enjoy broad-based contributions across our service
portfolio with particularly strong performances in our Auctions &
Competitive Bidding, Finance, Financial Economics, Forensic Services,
Intellectual Property, and Life Sciences practices.”
Outlook and Financial Guidance
“As these first quarter results demonstrate, we continue to see strong
demand for our portfolio of services. First quarter lead flow and new
project originations were up more than 5% and 10%, respectively, year
over year. For the full-year fiscal 2019, on a constant currency basis
relative to fiscal 2018, we are reaffirming our previous guidance of
revenue in the range of $430 million to $445 million, and non-GAAP
EBITDA margin in the range of 9.2% to 10.2%. While we are pleased with
our operational performance in the first quarter of fiscal 2019, we
remain mindful that uncertainties around global economic and political
conditions can affect our business,” Maleh concluded.
CRA does not provide reconciliations of its annual non-GAAP EBITDA
margin guidance to GAAP net income margin because CRA is unable to
estimate with reasonable certainty the revaluation of contingent
consideration liabilities, unusual gains or charges, foreign currency
exchange rates, and the resulting effect of these items, and of equity
awards, on CRA’s taxes without unreasonable effort. These items are
uncertain, depend on various factors, and may have a material effect on
CRA’s results computed in accordance with GAAP. A reconciliation between
the historical GAAP and non-GAAP financial measures presented in this
release is provided in the financial tables at the end of this release.
Quarterly Dividend
On May 2, 2019, CRA’s Board of Directors declared a quarterly cash
dividend of $0.20 per common share, payable on June 14, 2019 to
shareholders of record as of May 28, 2019. CRA expects to continue
paying quarterly dividends, the declaration, timing and amounts of which
remain subject to the discretion of CRA’s Board of Directors.
Conference Call Information and Prepared CFO Remarks
CRA will host a conference call today at 10:00 a.m. ET to discuss its
first-quarter 2019 financial results. To listen to the live call, please
visit the “Investor
Relations” section of CRA’s website at http://www.crai.com,
or dial (877) 709-8155 or (201) 689-8881. An archived
version of the webcast will be available on CRA’s website for one year.
In combination with this press release, CRA has posted prepared remarks
by its CFO Chad Holmes under “Conference
Call Materials” in the “Investor
Relations” section on CRA’s website at http://www.crai.com.
These remarks are offered to provide the investment community with
additional background on CRA’s financial results prior to the start of
the conference call.
About Charles River Associates (CRA)
Charles River Associates® is a leading global consulting firm
specializing in economic,
financial, and management consulting services. CRA advises clients
on economic and financial matters pertaining to litigation and
regulatory proceedings, and guides corporations through critical
business strategy and performance-related issues. Since 1965, clients
have engaged CRA for its unique combination of functional expertise and
industry knowledge, and for its objective solutions to complex problems.
Headquartered in Boston, CRA has offices throughout the world. Detailed
information about Charles River Associates, a registered trade name of
CRA International, Inc., is available at www.crai.com.
Follow us on LinkedIn,
Twitter,
and Facebook.
NON-GAAP FINANCIAL MEASURES
In this release, CRA has supplemented the presentation of its financial
results calculated in accordance with U.S. generally accepted accounting
principles or “GAAP” with financial measures that were not calculated in
accordance with GAAP. CRA believes that the non-GAAP financial measures
described in this press release are important to management and
investors because these measures supplement the understanding of CRA’s
ongoing operating results and financial condition. In addition, these
non-GAAP measures are used by CRA in its budgeting process, and the
non-GAAP adjustments described below are made to the performance
measures for some of CRA’s performance-based compensation.
The adjustments made to the financial measures identified in this
release as “non-GAAP” are as follows: for the first quarter of fiscal
2019, the adjustments exclude non-cash amounts relating principally to
valuation changes in contingent consideration; for the first quarter of
fiscal 2018, the adjustments exclude non-cash amounts relating
principally to valuation changes in contingent consideration, and net
costs related to lease recapture. This release also presents certain
current fiscal period financial measures on a “constant currency” basis
in order to isolate the effect that foreign currency exchange rate
fluctuations can have on CRA’s financial results. These constant
currency measures are determined by recalculating the current fiscal
period local currency financial measure using the specified
corresponding prior fiscal period’s foreign exchange rates. Finally,
this release also presents the non-GAAP financial metric EBITDA.
All of the non-GAAP financial measures referred to above should be
considered in conjunction with, and not as a substitute for, the GAAP
financial information presented in this release. EBITDA and the
financial measures identified in this release as “non-GAAP” are
reconciled to their GAAP comparable measures in the financial tables
appended to the end of this press release. In evaluating these non-GAAP
financial measures, note that the non-GAAP financial measures used by
CRA may be calculated differently from, and therefore may not be
comparable to, similarly titled measures used by other companies.
SAFE HARBOR STATEMENT
Statements in this press release concerning our future business,
operating results and financial condition, including those concerning
guidance on future revenue and non-GAAP EBITDA margin, the impact of
exchange rate fluctuations on our financial results, the continuation of
or building on any trend or momentum, our expectations regarding the
payment of any future quarterly dividends, and statements using the
terms “outlook,” “expect,” or similar expressions, are “forward-looking”
statements as defined in Section 21 of the Exchange Act. These
statements are based upon our current expectations and various
underlying assumptions. Although we believe there is a reasonable basis
for these statements and assumptions, and these statements are expressed
in good faith, these statements are subject to a number of additional
factors and uncertainties. Our actual revenue and non-GAAP EBITDA margin
in fiscal 2019 on a constant currency basis relative to fiscal 2018
could differ materially from the guidance presented herein, and our
actual performance and results may differ materially from the
performance and results contained in or implied by the other
forward-looking statements made herein, due to many important factors.
These factors include, but are not limited to, the possibility that the
demand for our services may decline as a result of changes in general
and industry specific economic conditions; the timing of engagements for
our services; the effects of competitive services and pricing; our
ability to attract and retain key employee or non-employee experts; the
inability to integrate and utilize existing consultants and personnel;
the decline or reduction in project work or activity; global economic
conditions including less stable political and economic environments;
foreign currency exchange rate fluctuations; unanticipated expenses and
liabilities; risks inherent in international operations; changes in tax
law or accounting standards, rules, and regulations; our ability to
collect on forgivable loans should any become due; and professional and
other legal liability or settlements. Additional risks and uncertainties
are discussed in our periodic filings with the Securities and Exchange
Commission under the heading “Risk Factors.” The inclusion of such
forward-looking information should not be regarded as our representation
that the future events, plans, or expectations contemplated will be
achieved. We undertake no obligation to update any forward-looking
statements after the date of this press release, and we do not intend to
do so.
CRA INTERNATIONAL, INC. | ||||||||||||||||||||||||||||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS INCLUDING A RECONCILIATION TO NON-GAAP RESULTS |
||||||||||||||||||||||||||||||||||||||
FOR THE QUARTER ENDED MARCH 30, 2019 COMPARED TO THE QUARTER ENDED MARCH 31, 2018 |
||||||||||||||||||||||||||||||||||||||
(In thousands, except per share data) | ||||||||||||||||||||||||||||||||||||||
Quarter Ended March 30, 2019 | Quarter Ended March 31, 2018 | |||||||||||||||||||||||||||||||||||||
GAAP | Non-GAAP | GAAP | Non-GAAP | |||||||||||||||||||||||||||||||||||
GAAP | % of | Adjustments to | Non-GAAP | % of | GAAP | % of | Adjustments to | Non-GAAP | % of | |||||||||||||||||||||||||||||
Results | Revenues | GAAP Results (1) | Results | Revenues | Results | Revenues | GAAP Results (2) | Results | Revenues | |||||||||||||||||||||||||||||
Revenues | $ | 105,849 | 100.0 | % | $ | – | $ | 105,849 | 100.0 | % | $ | 99,476 | 100.0 | % | $ | – | $ | 99,476 | 100.0 | % | ||||||||||||||||||
Cost of services (exclusive of depreciation and amortization) | 73,635 | 69.6 | % | (217 | ) | 73,852 | 69.8 | % | 69,391 | 69.8 | % | (107 | ) | 69,498 | 69.9 | % | ||||||||||||||||||||||
Selling, general and administrative expenses | 22,743 | 21.5 | % | – | 22,743 | 21.5 | % | 21,650 | 21.8 | % | 555 | 21,095 | 21.2 | % | ||||||||||||||||||||||||
Depreciation and amortization | 2,616 | 2.5 | % | – | 2,616 | 2.5 | % | 2,231 | 2.2 | % | – | 2,231 | 2.2 | % | ||||||||||||||||||||||||
Income (loss) from operations | 6,855 | 6.5 | % | 217 | 6,638 | 6.3 | % | 6,204 | 6.2 | % | (448 | ) | 6,652 | 6.7 | % | |||||||||||||||||||||||
Interest and other income (expense), net | (755 | ) | -0.7 | % | – | (755 | ) | -0.7 | % | (278 | ) | -0.3 | % | – | (278 | ) | -0.3 | % | ||||||||||||||||||||
Income (loss) before provision for income taxes and | ||||||||||||||||||||||||||||||||||||||
noncontrolling interest | 6,100 | 5.8 | % | 217 | 5,883 | 5.6 | % | 5,926 | 6.0 | % | (448 | ) | 6,374 | 6.4 | % | |||||||||||||||||||||||
Provision for income taxes | 1,435 | 1.4 | % | 58 | 1,377 | 1.3 | % | 1,040 | 1.0 | % | (68 | ) | 1,108 | 1.1 | % | |||||||||||||||||||||||
Net income (loss) | 4,665 | 4.4 | % | 159 | 4,506 | 4.3 | % | 4,886 | 4.9 | % | (380 | ) | 5,266 | 5.3 | % | |||||||||||||||||||||||
Net (income) loss attributable to noncontrolling interests, net of tax |
– | 0.0 | % | – | – | 0.0 | % | – | 0.0 | % | – | – | 0.0 | % | ||||||||||||||||||||||||
Net income (loss) attributable to CRA International, Inc. | $ | 4,665 | 4.4 | % | $ | 159 | $ | 4,506 | 4.3 | % | $ | 4,886 | 4.9 | % | $ | (380 | ) | $ | 5,266 | 5.3 | % | |||||||||||||||||
Net Income (loss) per share attributable to CRA International, Inc.: | ||||||||||||||||||||||||||||||||||||||
Basic | $ | 0.58 | $ | 0.56 | $ | 0.59 | $ | 0.63 | ||||||||||||||||||||||||||||||
Diluted | $ | 0.56 | $ | 0.54 | $ | 0.57 | $ | 0.61 | ||||||||||||||||||||||||||||||
Weighted average number of shares outstanding: | ||||||||||||||||||||||||||||||||||||||
Basic | 8,015 | 8,015 | 8,285 | 8,285 | ||||||||||||||||||||||||||||||||||
Diluted | 8,346 | 8,346 | 8,580 | 8,580 | ||||||||||||||||||||||||||||||||||
(1) These adjustments relate principally to non-cash valuation changes in contingent consideration. |
||||||||||||||||||||||||||||||||||||||
(2) These adjustments relate principally to non-cash valuation changes in contingent consideration and net costs related to a lease recapture. |
||||||||||||||||||||||||||||||||||||||
CRA INTERNATIONAL, INC. | |||||||||||||||||||||||||||||||||
UNAUDITED NON-GAAP EBITDA AND RECONCILIATION TO NET INCOME | |||||||||||||||||||||||||||||||||
FOR THE FISCAL QUARTER ENDED MARCH 30, 2019 COMPARED TO THE FISCAL QUARTER ENDED MARCH 31, 2018 |
|||||||||||||||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||||||||||||
Quarter Ended March 30, 2019 | Quarter Ended March 31, 2018 | ||||||||||||||||||||||||||||||||
GAAP | Non-GAAP | GAAP | Non-GAAP | ||||||||||||||||||||||||||||||
GAAP | % of | Adjustments to | Non-GAAP | % of | GAAP | % of | Adjustments to | Non-GAAP | % of | ||||||||||||||||||||||||
Results | Revenues | GAAP Results (1) | Results | Revenues | Results | Revenues | GAAP Results (2) | Results | Revenues | ||||||||||||||||||||||||
Revenues | $ | 105,849 | 100.0 | % | $ | – | $ | 105,849 | 100.0 | % | $ | 99,476 | 100.0 | % | $ | – | $ | 99,476 | 100.0 | % | |||||||||||||
Net income (loss) attributable to CRA International, Inc. | $ | 4,665 | 4.4 | % | $ | 159 | $ | 4,506 | 4.3 | % | $ | 4,886 | 4.9 | % | $ | (380 | ) | $ | 5,266 | 5.3 | % | ||||||||||||
Net income (loss) attributable to noncontrolling interests, net of tax |
– | 0.0 | % | – | – | 0.0 | % | – | 0.0 | % | – | – | 0.0 | % | |||||||||||||||||||
Net income (loss) | 4,665 | 4.4 | % | 159 | 4,506 | 4.3 | % | 4,886 | 4.9 | % | (380 | ) | 5,266 | 5.3 | % | ||||||||||||||||||
Interest expense, net | 11 | 0.0 | % | – | 11 | 0.0 | % | 37 | 0.0 | % | – | 37 | 0.0 | % | |||||||||||||||||||
Provision for income taxes | 1,435 | 1.4 | % | 58 | 1,377 | 1.3 | % | 1,040 | 1.0 | % | (68 | ) | 1,108 | 1.1 | % | ||||||||||||||||||
Depreciation and amortization | 2,616 | 2.5 | % | – | 2,616 | 2.5 | % | 2,231 | 2.2 | % | – | 2,231 | 2.2 | % | |||||||||||||||||||
EBITDA | $ | 8,727 | 8.2 | % | $ | 217 | $ | 8,510 | 8.0 | % | $ | 8,194 | 8.2 | % | $ | (448 | ) | $ | 8,642 | 8.7 | % | ||||||||||||
(1) These adjustments relate principally to non-cash valuation changes in contingent consideration. |
|||||||||||||||||||||||||||||||||
(2) These adjustments relate principally to non-cash valuation changes in contingent consideration and net costs related to a lease recapture. |
|||||||||||||||||||||||||||||||||
CRA INTERNATIONAL, INC. | |||||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
(In thousands) | |||||||
March 30, | December 29, | ||||||
2019 | 2018 | ||||||
Assets | |||||||
Cash and cash equivalents | $ | 14,958 | $ | 38,028 | |||
Accounts receivable and unbilled services, net | 134,231 | 130,585 | |||||
Other current assets | 17,584 | 12,527 | |||||
Total current assets | 166,773 | 181,140 | |||||
Property and equipment, net | 48,409 | 48,088 | |||||
Goodwill and intangible assets, net | 96,011 | 96,054 | |||||
Right-of-Use Assets | 81,480 | – | |||||
Other assets | 59,102 | 45,564 | |||||
Total assets | $ | 451,775 | $ | 370,846 | |||
Liabilities and shareholders’ equity | |||||||
Accounts payable | $ | 22,530 | $ | 21,938 | |||
Accrued expenses | 72,280 | 108,233 | |||||
Revolving line of credit | 39,000 | – | |||||
Current portion of lease liabilities | 9,558 | – | |||||
Other current liabilities | 6,056 | 12,326 | |||||
Total current liabilities | 149,424 | 142,497 | |||||
Non-current portion of lease liabilities | 94,939 | – | |||||
Other non-current liabilities | 9,522 | 31,877 | |||||
Total liabilities | 253,885 | 174,374 | |||||
Total shareholders’ equity | 197,890 | 196,472 | |||||
Total liabilities and shareholders’ equity | $ | 451,775 | $ | 370,846 | |||
CRA INTERNATIONAL, INC. |
|||||||||
Quarter Ended | Quarter Ended | ||||||||
March 30, | March 31, | ||||||||
2019 | 2018 | ||||||||
Operating activities: | |||||||||
Net income | $ | 4,665 | $ | 4,886 | |||||
Adjustments to reconcile net income to net cash | |||||||||
used in operating activities: | |||||||||
Non-cash items, net | 5,840 | 5,517 | |||||||
Accounts receivable and unbilled services | (2,924 | ) | (5,436 | ) | |||||
Working capital items, net | (64,148 | ) | (45,506 | ) | |||||
Net cash used in operating activities | (56,567 | ) | (40,539 | ) | |||||
Investing activities: | |||||||||
Purchases of property and equipment | (774 | ) | (3,248 | ) | |||||
Net cash used in investing activities | (774 | ) | (3,248 | ) | |||||
Financing activities: | |||||||||
Issuance of common stock, principally stock option exercises | 1,526 | 535 | |||||||
Borrowings under revolving line of credit | 39,000 | 10,000 | |||||||
Tax withholding payments reimbursed by shares | (388 | ) | (1,783 | ) | |||||
Cash paid on dividend equivalents | (35 | ) | (98 | ) | |||||
Cash dividend paid to shareholders | (1,616 | ) | (1,423 | ) | |||||
Repurchases of common stock | (4,349 | ) | (7,230 | ) | |||||
Net cash provided by financing activities | 34,138 | 1 | |||||||
Effect of foreign exchange rates on cash and cash equivalents | 133 | 603 | |||||||
Net decrease in cash and cash equivalents | (23,070 | ) | (43,183 | ) | |||||
Cash and cash equivalents at beginning of period | 38,028 | 54,035 | |||||||
Cash and cash equivalents at end of period | $ | 14,958 | $ | 10,852 | |||||
Noncash investing and financing activities: | |||||||||
Repurchases of common stock payable | $ | – | $ | 1,095 | |||||
Purchases of property and equipment not yet paid for | $ | 1,906 | $ | 3,923 | |||||
Asset retirement obligations | $ | – | $ | 223 | |||||
Right-of-use assets obtained in exchange for lease obligations | $ | 713 | $ | – | |||||
Right-of-use assets related to the adoption of ASC 842 | $ | 82,329 | $ | – | |||||
Supplemental cash flow information: | |||||||||
Cash paid for taxes | $ | 298 | $ | 212 | |||||
Cash paid for interest | $ | 59 | $ | 60 |
Contacts
Chad Holmes
Chief Financial Officer
Charles River Associates
312-377-2322
Jamie
Bernard, IRC
Senior Associate
Sharon Merrill Associates, Inc.
617-542-5300
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives
Cannabis
Rubicon Organics Reports Q1 2024 Financial Results
SCHWAZZE
Schwazze Announces First Quarter 2024 Financial Results
Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time
DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.
“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”
“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”
“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”
“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”
First Quarter 2024 Financial Summary
$ in Thousands USD |
Q1 2024 |
Q4 2023 |
Q1 2023 |
Total Revenue |
$41,601 |
$43,325 |
$40,001 |
Gross Profit |
$17,934 |
$7,034[1] |
$21,849 |
Operating Expenses |
$20,643 |
$23,276 |
$16,199 |
Income (Loss) from Operations |
$(2,709) |
$(16,242) |
$5,650 |
Adjusted EBITDA[2] |
$7,341 |
$10,953 |
$14,525 |
Operating Cash Flow |
$(3,700) |
$3,452 |
$(880) |
Recent Highlights
- Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
- Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
- Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
- Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.
First Quarter 2024 Financial Results
Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.
Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.
____________________________ |
1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. |
Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.
Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.
Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.
As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.
Conference Call
The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.
Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].
Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call
The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.
Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
About Schwazze
Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars
March 31, |
December 31, |
||||
2024 |
2023 |
||||
ASSETS
|
|||||
Current Assets |
|||||
Cash & Cash Equivalents |
$ |
13,151,317 |
$ |
19,248,932 |
|
Accounts Receivable, net of Allowance for Doubtful Accounts |
3,356,032 |
4,261,159 |
|||
Inventory |
26,382,184 |
25,787,793 |
|||
Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively |
108,583 |
456,099 |
|||
Prepaid Expenses & Other Current Assets |
3,502,310 |
3,914,064 |
|||
Total Current Assets |
46,500,426 |
53,668,047 |
|||
Non-Current Assets |
|||||
Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively |
31,326,000 |
31,113,630 |
|||
Investments |
2,000,000 |
2,000,000 |
|||
Investments Held for Sale |
– |
202,111 |
|||
Goodwill |
67,492,705 |
67,499,199 |
|||
Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively |
162,391,482 |
166,167,877 |
|||
Other Non-Current Assets |
1,328,187 |
1,263,837 |
|||
Operating Lease Right of Use Assets |
34,575,832 |
34,233,142 |
|||
Deferred Tax Assets, net |
992,144 |
1,996,489 |
|||
Total Non-Current Assets |
300,106,350 |
304,476,285 |
|||
Total Assets |
$ |
346,606,776 |
$ |
358,144,332 |
|
LIABILITIES & STOCKHOLDERS’ EQUITY
|
|||||
Current Liabilities |
|||||
Accounts Payable |
$ |
9,443,233 |
$ |
13,341,561 |
|
Accrued Expenses |
8,106,618 |
7,774,691 |
|||
Derivative Liabilities |
1,319,845 |
638,020 |
|||
Lease Liabilities – Current |
5,186,316 |
4,922,724 |
|||
Current Portion of Long Term Debt |
29,579,713 |
3,547,011 |
|||
Income Taxes Payable |
28,235,039 |
25,232,782 |
|||
Total Current Liabilities |
81,870,764 |
55,456,789 |
|||
Non-Current Liabilities |
|||||
Long Term Debt, net of Debt Discount & Issuance Costs |
130,120,753 |
153,262,203 |
|||
Lease Liabilities – Non-Current |
30,735,072 |
30,133,452 |
|||
Total Non-Current Liabilities |
160,855,825 |
183,395,655 |
|||
Total Liabilities |
$ |
242,726,589 |
$ |
238,852,444 |
|
Stockholders’ Equity |
|||||
Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and |
|||||
82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of |
|||||
December 31, 2023. |
82 |
86 |
|||
Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued |
|||||
and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued |
|||||
and 73,968,242 Shares Outstanding as of December 31, 2023. |
79,169 |
74,888 |
|||
Additional Paid-In Capital |
202,677,665 |
202,040,968 |
|||
Accumulated Deficit |
(96,843,602) |
(80,790,927) |
|||
Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and |
|||||
920,150 Shares Held as of December 31, 2023. |
(2,033,127) |
(2,033,127) |
|||
Total Stockholders’ Equity |
103,880,187 |
119,291,888 |
|||
Total Liabilities & Stockholders’ Equity |
$ |
346,606,776 |
$ |
358,144,332 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Operating Revenues |
|||||
Retail |
$ |
37,633,252 |
$ |
35,820,111 |
|
Wholesale |
3,898,320 |
4,058,925 |
|||
Other |
69,421 |
121,900 |
|||
Total Revenue |
41,600,993 |
40,000,936 |
|||
Total Cost of Goods & Services |
23,667,319 |
18,152,163 |
|||
Gross Profit |
17,933,674 |
21,848,773 |
|||
Operating Expenses |
|||||
Selling, General and Administrative Expenses |
11,835,818 |
10,100,934 |
|||
Professional Services |
1,671,881 |
1,187,364 |
|||
Salaries |
6,880,988 |
4,695,971 |
|||
Stock Based Compensation |
253,916 |
214,544 |
|||
Total Operating Expenses |
20,642,603 |
16,198,813 |
|||
Income from Operations |
(2,708,929) |
5,649,960 |
|||
Other Income (Expense) |
|||||
Interest Expense, net |
(8,307,369) |
(7,745,854) |
|||
Unrealized Gain (Loss) on Derivative Liabilities |
(681,825) |
8,501,685 |
|||
Other Loss |
10,500 |
– |
|||
Loss on Investment |
(33,382) |
– |
|||
Unrealized Gain on Investment |
(347,516) |
1,816 |
|||
Total Other Income (Expense) |
(9,359,592) |
757,647 |
|||
Pre-Tax Net Income (Loss) |
(12,068,521) |
6,407,607 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Less: Accumulated Preferred Stock Dividends for the Period |
(2,155,259) |
(2,029,394) |
|||
Net Income (Loss) Attributable to Common Stockholders |
$ |
(18,207,934) |
$ |
(283,965) |
|
Earnings (Loss) per Share Attributable to Common Stockholders |
|||||
Basic Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.01) |
|
Diluted Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.06) |
|
Weighted Average Number of Shares Outstanding – Basic |
76,006,932 |
55,835,501 |
|||
Weighted Average Number of Shares Outstanding – Diluted |
76,006,932 |
101,608,278 |
|||
Comprehensive Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Cash Flows from Operating Activities: |
|||||
Net Income (Loss) for the Period |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities |
|||||
Depreciation & Amortization |
5,096,314 |
6,151,395 |
|||
Non-Cash Interest Expense |
1,031,431 |
991,184 |
|||
Non-Cash Lease Expense |
2,871,226 |
2,251,459 |
|||
Deferred Taxes |
1,004,345 |
(637,225) |
|||
Loss on Investment |
202,111 |
– |
|||
Change in Derivative Liabilities |
681,825 |
(8,501,685) |
|||
Amortization of Debt Issuance Costs |
421,512 |
421,513 |
|||
Amortization of Debt Discount |
2,303,246 |
1,999,933 |
|||
(Gain) Loss on Investments, net |
347,516 |
(1,816) |
|||
Stock Based Compensation |
640,974 |
214,544 |
|||
Changes in Operating Assets & Liabilities (net of Acquired Amounts): |
|||||
Accounts Receivable |
905,127 |
(118,181) |
|||
Inventory |
(587,900) |
(3,023,251) |
|||
Prepaid Expenses & Other Current Assets |
411,754 |
(3,036,801) |
|||
Other Assets |
(64,350) |
360,674 |
|||
Change in Operating Lease Liabilities |
(2,348,703) |
(1,531,765) |
|||
Accounts Payable & Other Liabilities |
(3,566,401) |
(3,464,671) |
|||
Income Taxes Payable |
3,002,257 |
5,299,403 |
|||
Net Cash Provided by (Used in) Operating Activities |
(3,700,390) |
(879,861) |
|||
Cash Flows from Investing Activities: |
|||||
Collection of Notes Receivable |
– |
10,631 |
|||
Purchase of Fixed Assets |
(1,532,287) |
(2,913,394) |
|||
Net Cash Provided by (Used in) Investing Activities |
(1,532,287) |
(2,902,763) |
|||
Cash Flows from Financing Activities: |
|||||
Payment on Notes Payable |
(864,938) |
– |
|||
Net Cash Provided by (Used in) Financing Activities |
(864,938) |
– |
|||
Net (Decrease) in Cash & Cash Equivalents |
(6,097,615) |
(3,782,624) |
|||
Cash & Cash Equivalents at Beginning of Period |
19,248,932 |
38,949,253 |
|||
Cash & Cash Equivalents at End of Period |
$ |
13,151,317 |
$ |
35,166,628 |
|
Supplemental Disclosure of Cash Flow Information: |
|||||
Cash Paid for Interest |
$ |
4,515,205 |
$ |
6,540,748 |
MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Interest Expense, net |
8,307,369 |
7,745,854 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Other (Income) Expense, net of Interest Expense |
1,052,223 |
(8,503,501) |
|||
Depreciation & Amortization |
5,618,834 |
6,612,814 |
|||
Earnings Before Interest, Taxes, Depreciation and |
|||||
Amortization (EBITDA) (non-GAAP) |
$ |
2,909,905 |
$ |
12,262,774 |
|
Non-Cash Stock Compensation |
253,916 |
214,544 |
|||
Deal Related Expenses |
637,761 |
1,195,802 |
|||
Capital Raise Related Expenses |
20,760 |
35,068 |
|||
Severance |
484,561 |
118,436 |
|||
Retention Program Expenses |
807,500 |
280,632 |
|||
Pre-Operating & Dark Carry Expenses |
1,053,837 |
391,917 |
|||
One-Time Legal Settlements |
417,653 |
– |
|||
Other Non-Recurring Items |
754,751 |
25,707 |
|||
Adjusted EBITDA (non-GAAP) |
$ |
7,340,644 |
$ |
14,524,880 |
|
Revenue |
41,600,993 |
40,000,936 |
|||
Adjusted EBITDA Percent |
17.6 % |
36.3 % |
View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis1 week ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis5 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis5 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis4 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis3 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
SCHWAZZE3 days ago
Schwazze Announces First Quarter 2024 Financial Results